Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
124130723 | 12413072 | 3 | F | 20150409 | 20160920 | 20160527 | 20160929 | EXP | US-BAYER-2015-141559 | BAYER | 82.00 | YR | E | F | Y | 0.00000 | 20160929 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
124130723 | 12413072 | 1 | PS | NEXAVAR | SORAFENIB | 1 | Oral | 200 MG, QD | Y | 21923 | 200 | MG | FILM-COATED TABLET | QD | |||||
124130723 | 12413072 | 2 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 400 MG DAILY | Y | 21923 | 400 | MG | FILM-COATED TABLET | ||||||
124130723 | 12413072 | 3 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 200 MG, BID | Y | 21923 | 200 | MG | FILM-COATED TABLET | BID | |||||
124130723 | 12413072 | 4 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 200 MG, QD, EXCEPT ON WEDNESDAY AND SUNDAY | Y | 21923 | 200 | MG | FILM-COATED TABLET | QD | |||||
124130723 | 12413072 | 5 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 400 MG, QD | Y | 21923 | 400 | MG | FILM-COATED TABLET | QD | |||||
124130723 | 12413072 | 6 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | 0 | ||||||||||||
124130723 | 12413072 | 7 | C | METOPROLOL. | METOPROLOL | 1 | 0 | ||||||||||||
124130723 | 12413072 | 8 | C | SIMVASTATINE | SIMVASTATIN | 1 | 0 | ||||||||||||
124130723 | 12413072 | 9 | C | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
124130723 | 12413072 | 1 | Soft tissue sarcoma |
124130723 | 12413072 | 2 | Soft tissue sarcoma |
124130723 | 12413072 | 3 | Soft tissue sarcoma |
124130723 | 12413072 | 4 | Soft tissue sarcoma |
124130723 | 12413072 | 5 | Soft tissue sarcoma |
124130723 | 12413072 | 6 | Blood pressure increased |
124130723 | 12413072 | 7 | Blood pressure increased |
124130723 | 12413072 | 8 | Blood cholesterol increased |
124130723 | 12413072 | 9 | Blood glucose increased |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
124130723 | 12413072 | HO |
124130723 | 12413072 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
124130723 | 12413072 | Anal incontinence | |
124130723 | 12413072 | Aphasia | |
124130723 | 12413072 | Arthralgia | |
124130723 | 12413072 | Blood pressure increased | |
124130723 | 12413072 | Cerebrovascular accident | |
124130723 | 12413072 | Decreased appetite | |
124130723 | 12413072 | Depression | |
124130723 | 12413072 | Extremity contracture | |
124130723 | 12413072 | Fatigue | |
124130723 | 12413072 | Gastrointestinal haemorrhage | |
124130723 | 12413072 | General physical health deterioration | |
124130723 | 12413072 | Hyperaesthesia | |
124130723 | 12413072 | Hypoaesthesia | |
124130723 | 12413072 | Muscular weakness | |
124130723 | 12413072 | Neuropathy peripheral | |
124130723 | 12413072 | Off label use | |
124130723 | 12413072 | Osteopenia | |
124130723 | 12413072 | Pain in extremity | |
124130723 | 12413072 | Paraesthesia | |
124130723 | 12413072 | Peripheral swelling | |
124130723 | 12413072 | Urinary incontinence | |
124130723 | 12413072 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
124130723 | 12413072 | 1 | 201503 | 2015 | 0 | |
124130723 | 12413072 | 2 | 2015 | 20150506 | 0 | |
124130723 | 12413072 | 3 | 20150629 | 0 | ||
124130723 | 12413072 | 4 | 2015 | 0 |